Abstract
Introduction: Intravaginal delivery is currently considered to be an important alternative route for poorly-absorbed, rapidly metabolised oral drugs.
Objectives: The objective of this study was to evaluate (i) the preliminary feasibility of using the readyto- use vehicle Pentravan® to compound dienogest, gestrinone, nimesulide and piroxicam and (ii) the vaginal administration of theses formulations to patients with pelvic pain associated with endometriosis (PPRE).
Methods: Intravaginal creams were compounded containing the active pharmaceutical ingredients (APIs) individually and with no addition of permeation enhancers (dienogest 0,2%, gestrinone 0,5%, nimesulide 2,0% and piroxicam 2,0%). For quality control, pH, drug content and particle size were determined. HPLC methods were developed and validated for each formulation. Vaginal permeation profiles were determined using porcine vaginal mucosa on Franz-type diffusion cells and then kinetics parameters were determined.
Results: Quality control of the formulations showed that the products were convenient and easily prepared, with narrow size distribution. Diffusion experiments demonstrated fluxes of 15.98 µg.cm-2.h-1 for dienogest, 3.91 µg.cm-2.h-1 for piroxicam, 3.72 µg.cm-2.h-1 for gestrinone and 2.26 µg.cm-2.h-1 for nimesulide. Dienogest and gestrinone had permeation fluxes and quantities of drug absorbed hypothetically compatible with therapeutic effect in vivo (fluxes to attempt in order to deliver the recommended daily doses to treat PPRE were calculated as 0.87 µg.cm-2.h-1 for dienogest, 0.69 µg.cm-2.h-1 for gestrinone, 70.45 µg.cm-2.h-1 for nimesulide and 9.64 µg.cm-2.h-1 for piroxicam), whereas nimesulide and piroxicam studies showed a great amount of these drugs retained in the vaginal mucosa. This could account for a local effect for these two substances.
Conclusion: Pentravan®, which already has an established role for transdermal delivery of drugs, seems to be a feasible intravaginal vehicle. Particularly in this study, we highlight its use for vaginal delivery of dienogest and gestrinone for the treatment of PPRE. In vivo studies must now be conducted to confirm these data.
Keywords: Vaginal delivery, permeation kinetics, pentravan, franz-type diffusion cell, dienogest, gestrinone, nimesulide, piroxicam.
Graphical Abstract
Drug Delivery Letters
Title:Feasibility Study Evaluating Pentravan® for the Intravaginal Administration of Active Pharmaceutical Ingredients to Reduce Pelvic Pain Related to Endometriosis
Volume: 8 Issue: 3
Author(s): Hudson Polonini*, Sharlene Loures, Michele C. Alves, Anderson O. Ferreira, Marcos Antônio F. Brandão and Nádia R. B. Raposo
Affiliation:
- Ortofarma – Quality Control Laboratory, Matias Barbosa – MG,Brazil
Keywords: Vaginal delivery, permeation kinetics, pentravan, franz-type diffusion cell, dienogest, gestrinone, nimesulide, piroxicam.
Abstract: Introduction: Intravaginal delivery is currently considered to be an important alternative route for poorly-absorbed, rapidly metabolised oral drugs.
Objectives: The objective of this study was to evaluate (i) the preliminary feasibility of using the readyto- use vehicle Pentravan® to compound dienogest, gestrinone, nimesulide and piroxicam and (ii) the vaginal administration of theses formulations to patients with pelvic pain associated with endometriosis (PPRE).
Methods: Intravaginal creams were compounded containing the active pharmaceutical ingredients (APIs) individually and with no addition of permeation enhancers (dienogest 0,2%, gestrinone 0,5%, nimesulide 2,0% and piroxicam 2,0%). For quality control, pH, drug content and particle size were determined. HPLC methods were developed and validated for each formulation. Vaginal permeation profiles were determined using porcine vaginal mucosa on Franz-type diffusion cells and then kinetics parameters were determined.
Results: Quality control of the formulations showed that the products were convenient and easily prepared, with narrow size distribution. Diffusion experiments demonstrated fluxes of 15.98 µg.cm-2.h-1 for dienogest, 3.91 µg.cm-2.h-1 for piroxicam, 3.72 µg.cm-2.h-1 for gestrinone and 2.26 µg.cm-2.h-1 for nimesulide. Dienogest and gestrinone had permeation fluxes and quantities of drug absorbed hypothetically compatible with therapeutic effect in vivo (fluxes to attempt in order to deliver the recommended daily doses to treat PPRE were calculated as 0.87 µg.cm-2.h-1 for dienogest, 0.69 µg.cm-2.h-1 for gestrinone, 70.45 µg.cm-2.h-1 for nimesulide and 9.64 µg.cm-2.h-1 for piroxicam), whereas nimesulide and piroxicam studies showed a great amount of these drugs retained in the vaginal mucosa. This could account for a local effect for these two substances.
Conclusion: Pentravan®, which already has an established role for transdermal delivery of drugs, seems to be a feasible intravaginal vehicle. Particularly in this study, we highlight its use for vaginal delivery of dienogest and gestrinone for the treatment of PPRE. In vivo studies must now be conducted to confirm these data.
Export Options
About this article
Cite this article as:
Polonini Hudson*, Loures Sharlene, Alves C. Michele, Ferreira O. Anderson, Brandão Antônio F. Marcos and Raposo R. B. Nádia, Feasibility Study Evaluating Pentravan® for the Intravaginal Administration of Active Pharmaceutical Ingredients to Reduce Pelvic Pain Related to Endometriosis, Drug Delivery Letters 2018; 8 (3) . https://dx.doi.org/10.2174/2210303108666180319164824
DOI https://dx.doi.org/10.2174/2210303108666180319164824 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Proteomics
Current Proteomics Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets The Proteasome in Health and Disease
Current Pharmaceutical Design Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal Chemistry Loop Gain and Sleep Disordered Breathing
Current Respiratory Medicine Reviews The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Virus-Like Particles as Particulate Vaccines
Current HIV Research Novel Insights Into Lp(a) Physiology and Pathogenicity: More Questions Than Answers?
Cardiovascular & Hematological Disorders-Drug Targets Role of CNS Transporters in the Pharmacotherapy of HIV-1 Associated Neurological Disorders
Current Pharmaceutical Design Importance of Oxidative Damage on the Electron Transport Chain for the Rational Use of Mitochondria-Targeted Antioxidants
Mini-Reviews in Medicinal Chemistry Rapid Improvement of Canine Cognitive Dysfunction with Immunotherapy designed for Alzheimer's Disease
Current Alzheimer Research Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders
Current Topics in Medicinal Chemistry Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets PEDF and Septic Shock
Current Molecular Medicine Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPARα/γ
Current Signal Transduction Therapy Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research
Current Topics in Medicinal Chemistry Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery